Amarin Corp PLC (NAS:AMRN)
$ 0.5593 0.007 (1.27%) Market Cap: 230.06 Mil Enterprise Value: -70.17 Mil PE Ratio: 0 PB Ratio: 0.43 GF Score: 37/100

Amarin Corporation PLC at Citi Biotech Conference Transcript

Sep 04, 2019 / 06:15PM GMT
Release Date Price: $16.14 (+9.42%)
Joel Lawrence Beatty
Citigroup Inc, Research Division - VP & Analyst

Thank you for joining us. As you know, I'm Joel Beatty, one of the Citi's biotech analyst. And I'm pleased to have with me John Thero, CEO of Amarin.

Questions & Answers

Joel Lawrence Beatty
Citigroup Inc, Research Division - VP & Analyst

So let's get started with -- talking about Europe, for Amarin, given that the EFC cardiology conference just wrapped up over the last few days. I mean, I think -- and one thing that came out it is new guidelines and Europe recommends the use of Vascepa in patients with triglycerides 135 and up. Can you talk a little bit about the development for that for Amarin in Vascepa?

John F. Thero
Amarin Corporation plc - President, CEO & Director

Sure. I mean, before I get started here, I will, through my comments, be making forward-looking statements. And there are risks associated with all forward-looking statements, and I suggest that investors review our SEC filings and risk factors before

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot